Pfizer Inc. and BioNTech SE have announced that the European Medicines Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has recommended marketing authorization for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for active immunization in individuals aged 6 months and older. This recommendation is based on evidence supporting the safety and efficacy of the vaccine, which targets the LP.8.1 variant to maintain vaccine effectiveness as SARS-CoV-2 continues to evolve. The European Commission is expected to make a final decision soon. Pfizer and BioNTech have already started manufacturing the vaccine to ensure readiness for the upcoming fall and winter season.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.